HIV and cardiovascular disease: the role of inflammation.
Journal
Current opinion in HIV and AIDS
ISSN: 1746-6318
Titre abrégé: Curr Opin HIV AIDS
Pays: United States
ID NLM: 101264945
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
10
8
2022
Statut:
ppublish
Résumé
HIV and antiretroviral therapy (ART) use are linked to an increased incidence of atherosclerotic cardiovascular disease (ASCVD). Immune activation persists in ART-treated people with HIV (PWH), and markers of inflammation (i.e. IL-6, C-reactive protein) predict mortality in this population. This review discusses underlying mechanisms that likely contribute to inflammation and the development of ASCVD in PWH. Persistent inflammation contributes to accelerated ASCVD in HIV and several new insights into the underlying immunologic mechanisms of chronic inflammation in PWH have been made (e.g. clonal haematopoiesis, trained immunity, lipidomics). We will also highlight potential pro-inflammatory mechanisms that may differ in vulnerable populations, including women, minorities and children. Mechanistic studies into the drivers of chronic inflammation in PWH are ongoing and may aid in tailoring effective therapeutic strategies that can reduce ASCVD risk in this population. Focus should also include factors that lead to persistent disparities in HIV care and comorbidities, including sex as a biological factor and social determinants of health. It remains unclear whether ASCVD progression in HIV is driven by unique mediators (HIV itself, ART, immunodeficiency), or if it is an accelerated version of disease progression seen in the general population.
Identifiants
pubmed: 35938462
doi: 10.1097/COH.0000000000000755
pii: 01222929-202209000-00006
pmc: PMC9370832
mid: NIHMS1818900
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
286-292Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL158592
Pays : United States
Organisme : NICHD NIH HHS
ID : R21 HD106579
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI168630
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation 2018; 138:1100–1112.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506–2512.
Gabuzda D, Jamieson BD, Collman RG, et al. Pathogenesis of aging and age-related comorbidities in people with HIV: highlights from the HIV ACTION Workshop. Pathog Immun 2020; 5:143–174.
Udo Hoffmann MTL, Foldyna B, Zanni MV, et al . Coronary artery disease, traditional risk, and inflammation among PWH in REPRIEVE. Conference on Retroviruses and Opportunistic Infections; Virtual 2022. https://www.croiconference.org/abstract/coronary-artery-disease-traditional-risk-and-inflammation-among-pwh-in-reprieve/ [Accessed 6–11 March 2021].
Fernandez DM, Rahman AH, Fernandez NF, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med 2019; 25:1576–1588.
Williams JW, Zaitsev K, Kim KW, et al. Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression. Nat Immunol 2020; 21:1194–1204.
Lavine KJ, Pinto AR, Epelman S, et al. The macrophage in cardiac homeostasis and disease: JACC Macrophage in CVD Series (Part 4). J Am Coll Cardiol 2018; 72:2213–2230.
Dragoljevic D, Westerterp M, Veiga CB, et al. Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis. Clin Sci (Lond) 2018; 132:1889–1899.
Dharan NJ, Yeh P, Bloch M, et al. HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. Nat Med 2021; 27:1006–1011.
van der Heijden WA, van Deuren RC, van de Wijer L, et al. Clonal hematopoiesis is associated with low CD4 nadir and increased residual HIV transcriptional activity in virally suppressed individuals with HIV. J Infect Dis 2022; 225:1339–1347.
Bick AG, Popadin K, Thorball CW, et al. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Sci Rep 2022; 12:577.
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–1371.
Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013; 26:2–18.
Somsouk M, Estes JD, Deleage C, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS 2015; 29:43–51.
Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromes. Blood 2012.
Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228–1238.
Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780–790.
Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis 2014; 210:1549–1554.
Happel AU, Barnabas SL, Froissart R, Passmore JS. Weighing in on the risks and benefits of probiotic use in HIV-infected and immunocompromised populations. Benef Microbes 2018; 9:239–246.
d’Ettorre G, Ceccarelli G, Giustini N, et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the “Probio-HIV” clinical trial. PLoS One 2015; 10:e0137200.
Serrano-Villar S, Vázquez-Castellanos JF, Vallejo A, et al. The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects. Mucosal Immunol 2017; 10:1279–1293.
Stiksrud B, Nowak P, Nwosu FC, et al. Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART. J Acquir Immune Defic Syndr 2015; 70:329–337.
Yang OO, Kelesidis T, Cordova R, Khanlou H. Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial. AIDS Res Hum Retroviruses 2014; 30:988–995.
Serrano-Villar S, de Lagarde M, Vázquez-Castellanos J, et al. Effects of immunonutrition in advanced human immunodeficiency virus disease: a randomized placebo-controlled clinical trial (Promaltia Study). Clin Infect Dis 2019; 68:120–130.
Santos A, Silveira EAD, Falco MO, et al. Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: randomized clinical trial. Clin Nutr 2017; 36:680–685.
Presti RM, Yeh E, Williams B, et al. A randomized, placebo-controlled trial assessing the effect of VISBIOME ES probiotic in people with HIV on antiretroviral therapy. Open Forum Infect Dis 2021; 8:ofab550.
Caroline E, Diggins SM, Douglas S Kwon, et al. Improving intestinal barrier using GLP-2 agonist reduces arterial inflammation in PWH. Conference on Retroviruses and Opportunistic Infections 2022; Virtual https://www.croiconference.org/abstract/statin-use-in-art-treated-hiv-reveals-an-altered-macrophage-transcriptomic-profile/ [Accessed 12–16th February 2022].
Zhao W, Wang X, Deik AA, et al. Elevated plasma ceramides are associated with antiretroviral therapy use and progression of carotid artery atherosclerosis in HIV infection. Circulation 2019; 139:2003–2011.
Chai JC, Deik AA, Hua S, et al. Association of lipidomic profiles with progression of carotid artery atherosclerosis in HIV infection. JAMA Cardiol 2019; 4:1239–1249.
Toledo E, Wang DD, Ruiz-Canela M, et al. Plasma lipidomic profiles and cardiovascular events in a randomized intervention trial with the Mediterranean diet. Am J Clin Nutr 2017; 106:973–983.
Chaudhary NS, Kind T, Willig AL, et al. Changes in lipidomic profile by antiretroviral treatment regimen: an ACTG 5257 ancillary study. Medicine (Baltimore) 2021; 100:e26588.
Bowman ER, Kulkarni M, Gabriel J, et al. Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy. Transl Med Commun 2020; 5:26.
Belury MA, Bowman E, Gabriel J, et al. Prospective analysis of lipid composition changes with antiretroviral therapy and immune activation in persons living with HIV. Pathog Immun 2017; 2:376–403.
Akerele OA, Cheema SK. Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis. Med Hypotheses 2015; 85:754–760.
Robblee MM, Kim CC, Porter Abate J, et al. Saturated fatty acids engage an IRE1alpha-dependent pathway to activate the NLRP3 inflammasome in myeloid cells. Cell Rep 2016; 14:2611–2623.
Martinelli N, Girelli D, Malerba G, et al. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr 2008; 88:941–949.
Fernandez C, Sandin M, Sampaio JL, et al. Plasma lipid composition and risk of developing cardiovascular disease. PLoS One 2013; 8:e71846.
Ueeda M, Doumei T, Takaya Y, et al. Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J 2008; 72:1836–1843.
Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007; 27:84–91.
Bowman ER, Kulkarni M, Gabriel J, et al. Altered lipidome composition is related to markers of monocyte and immune activation in antiretroviral therapy treated human immunodeficiency virus (HIV) infection and in uninfected persons. Front Immunol 2019; 10:785.
Maisa A, Hearps AC, Angelovich TA, et al. Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration. AIDS 2015; 29:1445–1457.
Bowman ER, Cameron CM, Richardson B, et al. Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to serum lipid profiles and activation indices: a model for studying atherogenic mechanisms. PLoS Pathog 2020; 16:e1008869.
Chaurasia B, Talbot CL, Summers SA. Adipocyte ceramides: the nexus of inflammation and metabolic disease. Front Immunol 2020; 11:576347.
Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr 2015; 68:396–404.
Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588–595.
Hileman CO, Turner R, Funderburg NT, et al. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS 2016; 30:65–73.
Ismail JC, Kumar C, Tamilselvan M, et al. Statin use in ART-treated HIV reveals an altered macrophage transcriptomic profile. Conference on Retroviruses and Opportunistic Infecitons 2022; Virtual https://www.croiconference.org/abstract/improving-intestinal-barrier-using-glp-2-agonist-reduces-arterial-inflammation-in-pwh/ [Accessed 12–16th February 2022].
Grinspoon SK, Fitch KV, Overton ET, et al. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J 2019; 212:23–35.
Saeed S, Quintin J, Kerstens HH, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 2014; 345:1251086.
Netea MG, Dominguez-Andres J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol 2020; 20:375–388.
Zhong C, Yang X, Feng Y, Yu J. Trained immunity: an underlying driver of inflammatory atherosclerosis. Front Immunol 2020; 11:284.
Lachmandas E, Boutens L, Ratter JM, et al. Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes. Nat Microbiol 2016; 2:16246.
Owen AM, Fults JB, Patil NK, et al. TLR agonists as mediators of trained immunity: mechanistic insight and immunotherapeutic potential to combat infection. Front Immunol 2020; 11:622614.
Merlini E, Tincati C, Biasin M, et al. Stimulation of PBMC and monocyte-derived macrophages via Toll-like receptor activates innate immune pathways in HIV-infected patients on virally suppressive combination antiretroviral therapy. Front Immunol 2016; 7:614.
Jalbert E, Crawford TQ, D’Antoni ML, et al. IL-1Beta enriched monocytes mount massive IL-6 responses to common inflammatory triggers among chronically HIV-1 infected adults on stable antiretroviral therapy at risk for cardiovascular disease. PLoS One 2013; 8:e75500.
van der Heijden WA, Van de Wijer L, Keramati F, et al. Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. JCI Insight 2021; 6:e145928.
Amma H, Naruse K, Ishiguro N, Sokabe M. Involvement of reactive oxygen species in cyclic stretch-induced NF-kappaB activation in human fibroblast cells. Br J Pharmacol 2005; 145:364–373.
Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 2009; 8:18–30.
Cillero-Pastor B, Carames B, Lires-Dean M, et al. Mitochondrial dysfunction activates cyclooxygenase 2 expression in cultured normal human chondrocytes. Arthritis Rheum 2008; 58:2409–2419.
Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging (Albany NY) 2012; 4:166–175.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377:1119–1131.
Singh MV, Kotla S, Le NT, et al. Senescent phenotype induced by p90RSK-NRF2 signaling sensitizes monocytes and macrophages to oxidative stress in HIV-positive individuals. Circulation 2019; 139:1199–1216.
Korencak M, Byrne M, Richter E, et al. Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI Insight 2019; 4:e126675.
Bowman ER, Cameron C, Richardson B, et al. In vitro exposure of leukocytes to HIV preexposure prophylaxis decreases mitochondrial function and alters gene expression profiles. Antimicrob Agents Chemother 2020; 65:e01755–20.
Wallace J, Gonzalez H, Rajan R, et al. Anti-HIV drugs cause mitochondrial dysfunction in monocyte-derived macrophages. Antimicrob Agents Chemother 2022; 66:e0194121.
Lightfoot M, Milburn N, Loeb Stanga L. Addressing health disparities in HIV: introduction to the special issue. J Acquir Immune Defic Syndr 2021; 88:S1–S5.
Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614–622.
Womack JA, Chang CC, So-Armah KA, et al. HIV infection and cardiovascular disease in women. J Am Heart Assoc 2014; 3:e001035.
Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US healthcare system. J Acquir Immune Defic Syndr 2012; 60:351–358.
Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737–1746.
Ticona E, Bull ME, Soria J, et al. Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy. AIDS 2015; 29:1617–1622.
Mathad JS, Gupte N, Balagopal A, et al. Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation. J Acquir Immune Defic Syndr 2016; 73:123–129.
Griesbeck M, Scully E, Altfeld M. Sex and gender differences in HIV-1 infection. Clin Sci (Lond) 2016; 130:1435–1451.
Dirajlal-Fargo S, Mussi-Pinhata MM, Weinberg A, et al. HIV-exposed uninfected infants have increased inflammation and monocyte activation. AIDS 2019; 33:845–853.
Siedner MJ, Zanni M, Tracy RP, et al. Increased systemic inflammation and gut permeability among women with treated HIV infection in rural Uganda. J Infect Dis 2018; 218:922–926.
Markella V, Zanni BF, Williams K, et al . Subclinical atherosclerosis and immune activation among US females vs males with HIV. Conference on Retroviruses and Opportunistic Infectious; Virtual 2022.
Lakoski SG, Herrington DM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric 2005; 8:317–326.
Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15:955–959.
Rizzetto L, Fava F, Tuohy KM, Selmi C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. J Autoimmun 2018; 92:12–34.
Dirajlal-Fargo S, El-Kamari V, Weiner L, et al. Altered intestinal permeability and fungal translocation in Ugandan children with human immunodeficiency virus. Clin Infect Dis 2020; 70:2413–2422.
Gosiker BJ, Lesko CR, Rich AJ, et al. Cardiovascular disease risk among transgender women living with HIV in the United States. PLoS One 2020; 15:e0236177.
Alzahrani T, Nguyen T, Ryan A, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes 2019; 12:e005597.
Streed CG Jr, Beach LB, Caceres BA, et al. Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association. Circulation 2021; 144:e136–e148.
Diamond LM, Dehlin AJ, Alley J. Systemic inflammation as a driver of health disparities among sexually-diverse and gender-diverse individuals. Psychoneuroendocrinology 2021; 129:105215.
Dirajlal-Fargo S, Albar Z, Sattar A, et al. Relationship between economic insecurity, inflammation, monocyte activation and intestinal integrity in children living with HIV in Uganda. AIDS Care 2020; 32:1451–1456.
McComsey GA, O’Riordan M, Hazen SL, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007; 21:921–927.
Ross AC, O’Riordan MA, Storer N, et al. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 2010; 211:492–498.
Sainz T, Alvarez-Fuente M, Navarro ML, et al. Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study. J Acquir Immune Defic Syndr 2014; 65:42–49.
Dirajlal-Fargo S, Albar Z, Bowman E, et al. Subclinical vascular disease in children with human immunodeficiency virus in Uganda is associated with intestinal barrier dysfunction. Clin Infect Dis 2020; 71:3025–3032.
Dirajlal-Fargo S, Albar Z, Bowman E, et al. Increased monocyte and T-cell activation in treated HIV+ Ugandan children: associations with gut alteration and HIV factors. AIDS 2020; 34:1009–1018.
Carrasco I, Tarancon-Diez L, Vázquez-Alejo E, et al. Innate and adaptive abnormalities in youth with vertically acquired HIV through a multicentre cohort in Spain. J Int AIDS Soc 2021; 24:e25804.
Eckard AR, Rosebush JC, Lee ST, et al. Increased immune activation and exhaustion in HIV-infected youth. Pediatr Infect Dis J 2016; 35:e370–e377.
Flygel TT, Sovershaeva E, Claassen-Weitz S, et al. Composition of gut microbiota of children and adolescents with perinatal human immunodeficiency virus infection taking antiretroviral therapy in Zimbabwe. J Infect Dis 2020; 221:483–492.
Kaur US, Shet A, Rajnala N, et al. High abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy. Sci Rep 2018; 8:17679.
Sessa L, Reddel S, Manno E, et al. Distinct gut microbiota profile in antiretroviral therapy-treated perinatally HIV-infected patients associated with cardiac and inflammatory biomarkers. AIDS 2019; 33:1001–1011.
Jao J, Jacobson DL, Russell JS, et al. Perinatally acquired HIV infection is associated with abnormal blood mitochondrial function during childhood/adolescence. AIDS 2021; 35:1385–1394.
Shen J, Liberty A, Shiau S, et al. Mitochondrial impairment in well suppressed children with perinatal HIV-infection on antiretroviral therapy. AIDS Res Hum Retroviruses 2020; 36:27–38.
Sereti I, Krebs SJ, Phanuphak N, et al. Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection. Clin Infect Dis 2017; 64:124–131.
Schnittman SR, Deitchman AN, Beck-Engeser G, et al. Abnormal levels of some biomarkers of immune activation despite very early treatment of human immunodeficiency virus. J Infect Dis 2021; 223:1621–1630.
Younas M, Psomas C, Reynes C, et al. Residual viremia is linked to a specific immune activation profile in HIV-1-infected adults under efficient antiretroviral therapy. Front Immunol 2021; 12:663843.
Younas M, Psomas C, Reynes C, et al. Microbial translocation is linked to a specific immune activation profile in HIV-1-infected adults with suppressed viremia. Front Immunol 2019; 10:2185.
Psomas C, Younas M, Reynes C, et al. One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: the ACTIVIH study. EBioMedicine 2016; 8:265–276.